In particular, upregulation of HGF or MSP showed be assessed as potential resistance pathways to CCL20-CCR6 targeting in colorectal cancer, and similarly, the efficacy of combinatorial approaches of blocking either or both the HGF-c-Met pathway or the MSP-MSPR pathway along with the CCL20-CCR6 pathway should be sought. The gene discussed is HGF; the disease is colorectal cancer.